These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37858248)

  • 21. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
    Chiba M; Shimono J; Ishio T; Takei N; Kasahara K; Ogasawara R; Ara T; Goto H; Izumiyama K; Otsuguro S; Perera LP; Hasegawa H; Maeda M; Hashino S; Maenaka K; Teshima T; Waldmann TA; Yang Y; Nakagawa M
    Blood; 2022 Nov; 140(18):1951-1963. PubMed ID: 35921533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen-specific tumor cell killing by cytotoxic T cells.
    Herzfeldt AK; Gamez MP; Martin E; Boryn LM; Baskaran P; Huber HJ; Schuler M; Park JE; Swee LK
    Elife; 2023 Sep; 12():. PubMed ID: 37732732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
    Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
    Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
    Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
    Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
    Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer.
    Liu J; Wei L; Hu N; Wang D; Ni J; Zhang S; Liu H; Lv T; Yin J; Ye M; Song Y
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
    Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
    Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
    Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
    PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer.
    Hu D; Shen W; Gong C; Fang C; Yao C; Zhu X; Wang L; Zhao C; Zhu S
    J Cell Mol Med; 2021 Mar; 25(6):2900-2908. PubMed ID: 33506637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
    Xia W; Chen J; Hou W; Chen J; Xiong Y; Li H; Qi X; Xu H; Xie Z; Li M; Zhang X; Li J
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer.
    Chen MC; Hung MY; Pan CM; Huang SW; Jan CI; Li YH; Chiu SC; Cho DY
    Cancer Sci; 2023 Jul; 114(7):2761-2773. PubMed ID: 37017116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.